2026– date –
-
Drug Discovery & DDS
Tuning siRNA Packing Order in Lipid Nanoparticles Controls Oligonucleotide Functional Delivery
bioRxiv (Preprint) International Overview This preprint investigates how tuning the siRNA packing order within lipid nanoparticles (LNPs) can modulate oligonucleotide functional delivery, addressing a key challenge in RNA therapeutics: e... -
New Technology
Insilico Medicine and Saudi Aramco Unveil ‘Sanity Pipeline’ for AI-Driven MOF Discovery
Insilico Medicine (Press Release), ChemRxiv (Preprint reference) Hong Kong Overview Insilico Medicine and Saudi Aramco have introduced the "Sanity Pipeline," an innovative AI-driven tool designed to tackle structural validity challenges ... -
Market Trends
CVS Caremark Expands Access to Eli Lilly’s Obesity Portfolio: Reinstates Zepbound, Adds Foundayo
FirstWord Pharma USA Overview CVS Caremark announced it will reinstate coverage for Eli Lilly's injectable weight-loss medication Zepbound (tirzepatide) and add the newly launched oral GLP-1 drug Foundayo (orforglipron) to its standard c... -
New Technology
Daiichi Sankyo Unveils Extensive Oncology Portfolio Progress at ASCO; Datopotamab Deruxtecan Approved for First-Line mTNBC
Daiichi Sankyo (Press Release), MedCity News, ADC Review, FirstWord Pharma Japan Overview Daiichi Sankyo will present over 25 abstracts at the 2026 ASCO Annual Meeting, showcasing its leading oncology portfolio, including new clinical da... -
New Technology
Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company (PRNewswire), Healthline, BioPharma Dive, The Guardian, BioSpace, GlobalData USA Overview Eli Lilly's triple hormone receptor agonist, retatrutide (GIP, GLP-1, and glucagon), demonstrated powerful and clinically mea... -
Market Trends
Key FDA Approvals Anticipated for GLP-1 Pipeline in May 2026 Update
Prime Therapeutics - Portal USA Overview Four significant FDA approval decisions for GLP-1 related medications are expected in 2026, marking critical advancements in metabolic disease management. Eli Lilly's injectable Mounjaro is antici... -
Drug Discovery & DDS
Eli Lilly Seals Landmark $2.75 Billion AI Drug Discovery Alliance with Insilico Medicine
IntuitionLabs, TipRanks, Tech Funding News USA Overview Pharmaceutical giant Eli Lilly has forged a strategic drug discovery and development collaboration with AI biotech pioneer Insilico Medicine, valued at up to $2.75 billion. The deal... -
Drug Discovery & DDS
European Biotechs Drive Next-Gen Cell & Gene Therapy Manufacturing Innovation
BioSpace UK Overview European biotechnology firms are making significant strides in cell and gene therapy (CGT) manufacturing, focusing on scalability and automation. UK-based Oxford Biomedica, a leading viral vector CDMO, specializes in... -
Solid-State Batteries
Nayuan New Materials Unveils Anode-Free All-Solid-State Sodium-Ion Battery with 320 Wh/kg Energy Density
Shanghai Metals Market China Overview Nayuan New Materials Technology (Wuxi) Co., Ltd. introduced an anode-free all-solid-state sodium-ion battery at the 2026 SMM Battery Technology Industry Conference. This novel battery boasts an energ... -
Solid-State Batteries
IPCO Showcases Enhanced Manufacturing Capabilities for Dry Electrode and Solid-State Batteries
electrive.com Germany Overview IPCO presented its expanded roll-to-roll and double belt press capabilities for continuous production of dry electrodes and solid-state batteries at The Battery Show Europe 2026. The acquisition of New Era ...